PSA screening remains highly controversial due to several important disadvantages. More PSA is produced with prostatic enlargement and in other benign conditions such as urinary tract infections. False positive tests can then lead to unnecessary diagnostic workup with invasive prostate biopsy. Another major problem with screening programs in general is overdiagnosis of cancers that would not have caused harm during the patient's lifetime. For example, many prostate cancers have a relatively indolent behavior so may not require diagnosis or treatment in a patient with limited life expectancy. All forms of prostate cancer treatment have potential urinary and sexual side effects, so reducing overdiagnosis and overtreatment are critical public health issues. Because screening has many proven benefits but also significant harms, there are widely disparate guidelines on prostate cancer screening from major organizations worldwide. This issue of the Urologic Clinics will provide insights into the many different prostate cancer guidelines and related policy issues.
PSA screening remains highly controversial due to several important disadvantages.
Dr. Samir Taneja, Consulting Editor, is stepping into the Guest Editor role for this issue of Urologic Clinics devoted to Prostate Cancer.
Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N EnglJ Med 2013;368(14):1314–25. Moinpour C, Berry DL, Ely B, et al. ... Tannock IF, de Wit R, Berry WR, et al.
Dr. Samir Taneja, Consulting Editor, is stepping into the Guest Editor role for this issue of Urologic Clinics devoted to Prostate Cancer.
In this issue of Urologic Clinics, guest editors Leonard G. Gomella and Veda Giri bring their considerable expertise to the topic of Prostate Cancer Genetics: Changing the Paradigm of Care.
This issue of Medical Clinics of North America, guest edited by Robert E. Brannigan, MD, is devoted to Urology.
Fujita K, Ewing CM, Sokoll LJ, etal. Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation. Prostate 2008;68(8):872–82. Schostak M, Schwall GP, ...
Clin Oncol (R Coll ... Weinstein HJ, Cassady JR, Levey R: Long-term results of the APO protocol (vincristine, doxorubicin [adriamycin], and prednisone) for treatment of ... Carachi R, Campbell PE, Kent M: Thoracic neural crest tumors.
Connolly JA, Shinohara K, Carroll PR. Cryosurgery for locally advanced (T3) prostate cancer. Semin Urol Oncol 1997;15:244–9. Donnelly BJ, Saliken JC, Ernst DS, et al. Prospective trial of cryosurgical ablation of the prostate: five-year ...
Samir S. Taneja. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. carcinoma of the bladder, the 2011 update.